Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7063104 | 0.89 | ALDH1A1 (0.37) | GAAL3MBTL1MEN1CYP3A4CYP2C9 | |
| SCHEMBL7061898 | 0.84 | GAA (0.47) | GAAL3MBTL1MEN1CYP3A4CYP2C9 | |
| SCHEMBL6680685 | 0.78 | MEN1 (0.33) | GAAL3MBTL1MEN1CYP3A4CYP2C9 | |
| SCHEMBL7057681 | 0.78 | CMA1 (0.30) | — | |
| SCHEMBL7061584 | 0.76 | MEN1 (0.32) | GAAL3MBTL1MEN1CYP3A4CYP2C9 | |
| SCHEMBL7062549 | 0.75 | ALDH1A1 (0.40) | GAAL3MBTL1MEN1CYP3A4CYP2C9 | |
| SCHEMBL7123002 | 0.75 | ALDH1A1 (0.38) | MEN1CYP3A4CYP2C9KMT2AALDH1A1 | |
| SCHEMBL6678802 | 0.70 | CMA1 (0.31) | — | |
| SCHEMBL7058527 | 0.69 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL6683791 | 0.67 | MEN1 (0.31) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | GAA 358/4885L3MBTL1 2277/4885MEN1 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.